Related Experiment Video
Updated: Dec 9, 2025
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
The P2X7 purinergic receptor: a potential therapeutic target for lung cancer
Qianqian Li1, Xiaodi Zhu1, Wei Song1
1School of Laboratory Medicine, Weifang Medical University, Weifang, Shandong, China.
Purpose:
Purinergic P2X7 receptor (P2X7R) is a gated ion channel for which adenosine triphosphate (ATP) is a ligand. Activated P2X7R is widely expressed in a variety of immune cells and tissues and is involved in a variety of physiological and pathological processes. Studies have confirmed that P2X7R is involved in the regulation of tumor cell growth, stimulating cell proliferation or inducing apoptosis. Recent studies have found that P2X7R is abnormally expressed in lung cancer and is closely related to the carcinogenesis and development of lung cancer. In this paper, we comprehensively describe the structure, function, and genetic polymorphisms of P2X7R. In particular, the role and therapeutic potential of P2X7R in lung cancer are discussed to provide new targets and new strategies for the treatment and prognosis of clinical lung cancer.
Methods:
The relevant literature on P2X7R and lung cancer from PubMed databases is reviewed in this article.
Results:
P2X7R regulates the function of lung cancer cells by activating multiple intracellular signaling pathways (such as the JNK, Rho, HMGB1 and EMT pathways), thereby affecting cell survival, growth, invasion, and metastasis and patient prognosis. Targeting P2X7R with inhibitors effectively suppresses the growth and metastasis of lung cancer cells.
Conclusion:
In summary, P2X7R is expected to become a potential target for the treatment of lung cancer, and more clinical research is needed in the future to explore the effectiveness of P2X7R antagonists as treatments.
Insights
The purinergic P2X7 receptor (P2X7R) plays a key role in lung cancer progression. Targeting P2X7R with inhibitors shows potential for suppressing tumor growth and metastasis, offering new therapeutic strategies.
Area of Science:
- Molecular biology
- Immunology
- Oncology
Background:
- The purinergic P2X7 receptor (P2X7R) is an ATP-gated ion channel expressed on immune cells.
- P2X7R is implicated in various physiological and pathological processes, including tumor cell proliferation and apoptosis.
- Abnormal P2X7R expression is linked to lung cancer development and progression.
Purpose of the Study:
- To review the structure, function, and genetic polymorphisms of P2X7R.
- To discuss the role and therapeutic potential of P2X7R in lung cancer.
- To identify P2X7R as a potential therapeutic target for lung cancer.
Main Methods:
- Literature review of studies on P2X7R and lung cancer.
- Analysis of P2X7R's involvement in intracellular signaling pathways.
- Evaluation of P2X7R inhibitors' effects on lung cancer cells.
Main Results:
- P2X7R regulates lung cancer cell survival, growth, invasion, and metastasis via pathways like JNK, Rho, HMGB1, and EMT.
- Inhibiting P2X7R effectively suppresses lung cancer cell growth and metastasis.
- P2X7R activity influences patient prognosis in lung cancer.
Conclusions:
- P2X7R is a promising therapeutic target for lung cancer treatment.
- Further clinical research is necessary to validate P2X7R antagonists for lung cancer therapy.
- Targeting P2X7R offers new strategies for improving lung cancer prognosis.
More Related Videos
11:47Real-time Live-cell Flow Cytometry to Investigate Calcium Influx, Pore Formation, and Phagocytosis by P2X7 Receptors in Adult Neural Progenitor Cells
Published on: April 3, 2019
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...